Last reviewed · How we verify
Artesunate plus Amodiaquine
Artesunate and amodiaquine work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.
Artesunate and amodiaquine work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae.
At a glance
| Generic name | Artesunate plus Amodiaquine |
|---|---|
| Also known as | Arsucam® |
| Sponsor | Bernhard Nocht Institute for Tropical Medicine |
| Drug class | Antimalarial combination therapy |
| Target | Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Artesunate, a semi-synthetic artemisinin derivative, rapidly reduces parasite biomass by generating free radicals that damage parasite proteins and membranes. Amodiaquine, a 4-aminoquinoline, inhibits parasite heme detoxification and DNA synthesis. The combination provides rapid parasite clearance and reduces the risk of resistance development through complementary mechanisms of action.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Diarrhea
- Pruritus
Key clinical trials
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar (PHASE3)
- OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (PHASE4)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (PHASE3)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (PHASE3)
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique (PHASE4)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: